A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationAleix Prat, PierFranco Conte, Valentina Guarneri et al.|The Lancet Oncology|2020Cited by 75
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancerMercedes Marín‐Aguilera, Laia Paré, A.G. Waks et al.|ESMO Open|2024Cited by 27
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1Fara Brasó‐Maristany, Valentina Guarneri, Gaia Griguolo et al.|JNCI Journal of the National Cancer Institute|2022Cited by 25
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1Esther Sanfeliu, Patricia Villagrasa, Fara Brasó‐Maristany et al.|UNC Libraries|2025Cited by 0